Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulin
Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health insurers.
Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the
Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
Senators question Novo Nordisk CEO on price of Ozempic
Lawmakers want to know why Americans pay so much more than other countries for weight loss drugs
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Novo Nordisk’s Wegovy-Fueled Gains Fading as Analyst Doubts Grow
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much as 4.6% to a seven-month low on Friday after a JPMorgan Chase & Co. analyst ...
Evotec and Novo Nordisk in technology development partnership
(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
Investing1d
Novo Nordisk A/S Class B (NOVOb)
Novo Nordisk (CO:NOVOb) (NVO -1.9%) submits a type 2 variation application to the European Medicines Agency (EMA) seeking approval to add data from two late-stage studies... LONDON (Reuters ...
$49.3 Bn GLP-1 Markets 2024-2035 with Boehringer Ingelheim, Eli Lilly, Novo Nordisk Dominating
Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 ...
Detroit News1d
Novo’s tough month key in ending health stocks’ winning streak
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over ...